Splenic Tyrosine Kinase Market Expected to surpass USD 300 Million By 2028 Says Kuick Research
Delhi, March 20, 2023 (GLOBE NEWSWIRE) -- Global SYK Inhibitors Market, Drug Price, Sales & Clinical Trials Outlook 2028 Report Highlights:
-
Global SYK Inhibitors Market Current & Forecast Sales
-
Global SYK Inhibitors Market Opportunity: > USD 300 Million
-
SYK Inhibitors Clinical Trials By Company, Country, Indication & Phase
-
Approved SYK Inhibitor Drug In market: 1 Drug (Fostamatinib)
-
Dosage, Patent, Price & Sales Insight On Fostamatinib
-
Competitive Landscape
Download Report: https://www.kuickresearch.com/report-syk-inhibitors-fostamatinib-market-sales-forecast-clinical-trials
After the role of the Syk protein was revealed in the development of cancer, it has been a subject for the development of many inhibitors. Currently, only one of these inhibitors in available in the market and the pipeline too, is moderately populated. The prosperous success of the approval Syk has undoubtedly played a major role in in the entry of newer drug candidates in the market. As the protein gains more attention as a potential targets, both the number of approvals and drugs in the pipeline are bound to increase.
Fostamatinib is currently the only Syk inhibitor in use since 2018. It has been developed by Rigel Pharmaceuticals and is indicated for the treatment of adult patients with chronic immune thrombocytopenia. The global revenue of the drug has been increasing every year being the first – in – class drug against the Syk protein. Additionally, another orally accessible SYK inhibitor TAK-659 has started clinical trials for individuals with advanced malignant solid tumors. Clinical studies showed proof of responsiveness, highlighting its potential in treatment of solid tumors.
Another Syk inhibitor candidate, Entospletinib had entered phase I clinical trials for the treatment of patients with NPM1-mutated acute myeloid leukemia (AML). In one study that paired entospletinib with traditional chemotherapy, patients with FLT3 abnormalities, MLL translocations, and NPM1 mutations had a larger than predicted complete response rate comparable with earlier counterparts. This set of trials for Entospletinib was started in November of 2021, and it was scheduled to end in 2026. However, a year later, in November of 2022, Kronos announced that the trial will not be continuing due to challenges in enrolling the subset of patients having the specified mutation. On the plus side, the company is still working on lanraplenib, a different Syk inhibitor candidate, which it plans to combine with Astellas Pharma's Xospata, another FLT3 inhibitor, to treat relapsed/refractory AML. This trial is in a phase 1b/2 trial currently.